← Eichor
Study identifier: NCT05180994 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Topical Infliximab in Eyes With Penetrating Keratoplasty

Condition: Glaucoma Following Surgery  ·  Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

PhasePhase 1/Phase 2
Planned participants50
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.

This description comes directly from the study's public registry record.

Talk to the study team

Zobelle Tchouaga  ·  514 890-8000  ·  zobelle.tchouaga.tongambou.chum@ssss.gouv.qc.ca

Always discuss trial participation with your own doctor first.

Locations (1)

Centre Hospitalier de l'Université de MontréalMontreal, Quebec, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05180994